Sedation outcomes for remimazolam, a new benzodiazepine
| Autor: | Ryutaro Kobayashi, Yoshiyuki Oi, Hitomi Satomi, Kaori Taguchi, Mie Kajiwara, Shunichi Oka, Reiko Sekino |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Benzodiazepine
medicine.drug_class business.industry Sedation Midazolam 030206 dentistry 03 medical and health sciences Benzodiazepines 0302 clinical medicine Anesthesia Sedative medicine Humans Hypnotics and Sedatives medicine.symptom Remimazolam business Adverse effect Propofol Complication General Dentistry 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of oral science. 63(3) |
| ISSN: | 1880-4926 |
| Popis: | Remimazolam is a new ultrashort-acting benzodiazepine with fast onset, quick recovery, and few side effects, such as hypotension and respiratory depression. It is expected to be safe and effective for a wide range of patients undergoing intravenous sedation for dental procedures. The aim of this literature review was to evaluate clinical and sedation outcomes for remimazolam, including method of administration, level of sedation at the dose required, and clinical adverse events. An electronic literature search of databases was conducted, and eight articles were selected for inclusion in this review. Onset time from drug administration to optimal sedation level was faster for remimazolam (around 1.5-6.4 min) than for midazolam. Recovery time was significantly shorter for remimazolam than for midazolam and propofol. A study comparing various doses of remimazolam with midazolam found no significant difference in safety. Comparison of a remimazolam group with a propofol group showed that incidences of hypotension (13.0% vs 42.9%, respectively) and respiratory depression (1.1% vs 6.9%, respectively) were significantly lower for remimazolam. Remimazolam appears to be an ideal sedative. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|